Phase III
Topline results from Agios Pharmaceuticals’ Phase III ACTIVATE trial show that treatment with mitapivat was associated with a significantly greater hemoglobin response compared with placebo in patients with pyruvate kinase deficiency.
Shares of Axsome were up more than 7% in premarket trading after the company announced positive, long-term results from its Phase III Major Depressive Disorder study that sets the company up for potential regulatory approval.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 1, 2020.
As the U.S. went into its Thanksgiving holiday week, clinical trial news was quieter than usual, although there was a lot of important news on the COVID-19 vaccine front. Here’s a look.
Despite the constant need for social distancing, mask-wearing, and the isolation and economic uncertainty that resulted from the outbreak, there is still much to be thankful for when families gather around a virtual table to break bread and carve the turkey this year.
Even companies with otherwise promising pipelines or successful products on the market sometimes face clinical trial failures. Two such companies had disappointing clinical trial announcements today.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 24, 2020.
Uveal melanoma is a rare and aggressive form of melanoma. It primarily affects the eye. There are no currently accepted optimal management regimens or treatments.
AstraZeneca and the University of Oxford announced results from an interim analysis of their COVID-19 vaccine, AZD1222. The analysis was from the trials in the UK and Brazil and demonstrated efficacy of up to 90%.
Although there was quite a bit of clinical trial news overall, the biggest focus was on COVID-19 vaccines, with the three leaders in the U.S. and Europe all presenting clinical trial news. Here’s a look.
PRESS RELEASES